T-DXd: Game-Changer in HER2+ Cancer

In this CHM Conversations clip, Drs. Paolo Tarantino and Jason Mouabbi discuss how trastuzumab deruxtecan (T-DXd) shattered expectations in HER2+ metastatic breast cancer, ushering in the definitive “post-T-DXd era.” DESTINY-Breast01 hinted at the extraordinary—durable responses where nothing else worked—while DESTINY-Breast03 delivered the decisive blow: T-DXd quadrupled median PFS over T-DM1 (29 months vs. 7 months), fueled by a cleavable linker, high drug-to-antibody ratio, and bystander effect. Practice changed overnight.

🔬 Topics Covered:
• T-DXd’s unprecedented efficacy in HER2+ mBC
• DESTINY-Breast01/03: from signal to standard
• Redefining second-line strategy post-T-DXd